Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.

This study examined whether HEGU and Licoricidin inhibit metastasis using the 4T1 mammary cancer model. Both HEGU and Licoricidin treatment reduced pulmonary metastasis and the expression of CD45, CD31, HIF-1α±, iNOS, COX-2, and VEGF-A in tumor tissues. Additionally, a decrease in protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 was noted in tumor tissues of Licoricidin-treated mice. Furthermore, the blood concentrations of MMP-9, ICAM-1, VCAM-1, and VEGF-A were decreased in HEGU-treated mice. In vitro 4T1 cell culture results showed that both HEGU and Licoricidin inhibited cell migration, MMP-9 secretion, and VCAM expression[1]

30508-27-1

C26H32O5

424.53

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years